Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lyra Therapeutics, Inc. (Nasdaq: LYRA) has announced an equity-based award for its new Senior Vice President of Investor Relations and Communications, Ellen Cavaleri, in accordance with Nasdaq Listing Rule 5635(c)(4). This inducement grant includes a non-qualified stock option to purchase 110,000 shares of the Company's common stock, approved by its independent directors. The company aims to leverage its XTreo™ platform for precise delivery of medications targeting ear, nose, and throat conditions, with ongoing product candidates like LYR-210 and LYR-220.
- Inducement grant of 110,000 stock options enhances company leadership.
- Focus on the XTreo™ platform supports innovation in drug delivery.
- None.
WATERTOWN, Mass., Sept. 13, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company, Lyra or Lyra Therapeutics), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that it has issued an equity-based award pursuant to its 2022 Inducement Award Plan to its Senior Vice President of Investor Relations and Communications, Ellen Cavaleri, upon the commencement of her employment. The inducement grant was approved by a majority of the Company's independent directors and was made as a material inducement to Ms. Cavaleri's acceptance of employment with Lyra in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of her employment compensation. The inducement grant consists of a non-qualified stock option to purchase an aggregate of 110,000 shares of the Company's common stock. The inducement grant is subject to the terms and conditions of the award agreement covering the performance stock option grant and the Company's 2022 Inducement Award Plan, as amended.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra's XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The Company's current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for up to six months following a single non-invasive, in-office administration. Lyra has two product candidates in late-stage development for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities: LYR-210, for surgically naïve patients, is being evaluated in the ENLIGHTEN Phase 3 clinical program, and LYR-220, for patients who have recurrent symptoms despite surgery, is being evaluated in the BEACON Phase 2 clinical trial. These two product candidates are designed to treat the estimated four million CRS patients in the U.S. that fail medical management each year. For more information, please visit lyratherapeutics.com and follow us on LinkedIn and Twitter.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Ellen Cavaleri's role at the Company, the Company's pipeline and development of product candidates, including LYR-210 and LYR-220, the progress and timing of clinical trials, movement toward commercialization, and the anticipated success of leveraging the XTreo™ platform. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the Company has incurred significant losses since inception and expects to incur additional losses for the foreseeable future; the Company's need for additional funding, which may not be available; the Company's limited operating history; the fact that the Company has no approved products; the fact that the Company's product candidates are in various stages of development; or the fact that the Company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the Company's product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the Company's product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the Company's inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the Company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the Company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the Company's reliance on third parties to conduct its preclinical studies and clinical trials; the Company's inability to succeed in establishing and maintaining collaborative relationships; the Company's reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the Company's intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the Company's growth; effects of natural disasters, terrorism and wars (including the developing conflict between Ukraine and Russia); the fact that the global pandemic caused by COVID-19 could adversely impact the Company's business and operations, including the Company's clinical trials; the fact that the price of the Company's common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2022 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.
Contact:
Kathryn Morris
The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lyra-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-301623626.html
SOURCE Lyra Therapeutics, Inc.
FAQ
What is the recent press release about Lyra Therapeutics?
What does the inducement grant for Ellen Cavaleri entail?
How does Lyra Therapeutics plan to use the XTreo™ platform?
What is the significance of Nasdaq Listing Rule 5635(c)(4) in this context?
What product candidates are currently in development by Lyra Therapeutics?
